Azithromycin: Indications, Dosing, and Contraindications
Azithromycin is a macrolide antibiotic with broad clinical utility, offering convenient once-daily dosing for respiratory tract infections, sexually transmitted infections, and pertussis, with specific age-based dosing regimens that must be carefully followed to optimize efficacy and minimize resistance.
Primary Indications
Respiratory Tract Infections
Community-Acquired Pneumonia (CAP)
- Atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae): Azithromycin is the preferred agent 1
Pertussis (Whooping Cough)
- Azithromycin is the first-line agent for all age groups, particularly critical for infants <1 month where it is preferred over erythromycin due to lower risk of infantile hypertrophic pyloric stenosis (IHPS) 2
Sexually Transmitted Infections
Chlamydial Infections
- Single-dose therapy is highly effective and preferred for compliance 3
Gonococcal Infections
- Azithromycin 2 g orally is used in combination therapy for treatment failures with ceftriaxone, though this is reserved for specific resistance scenarios 5
Other Infections
Babesiosis
- Combination therapy with atovaquone 6
- Pediatric: 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg (max 250 mg) daily
- Adult: 500 mg on day 1, then 250-500 mg daily for 7-10 days
Dosing Regimens by Age and Indication
Pediatric Dosing Framework
The standard pediatric regimen follows a loading dose approach:
- Day 1: 10 mg/kg (maximum 500 mg)
- Days 2-5: 5 mg/kg daily (maximum 250 mg per dose)
Alternative high-dose regimens (for specific indications like otitis media):
Adult Dosing Framework
- Standard 5-day course: 500 mg on day 1, then 250 mg daily on days 2-5
- Single-dose therapy: 1 g for chlamydial infections
- Extended therapy: 500 mg daily for severe infections or immunocompromised patients 6
Contraindications and Precautions
Absolute Contraindications
- Hypersensitivity to azithromycin or any macrolide antibiotic 2
- History of cholestatic jaundice or hepatic dysfunction with prior azithromycin use 7
Critical Warnings
Cardiac Considerations
- QTc prolongation risk: Azithromycin can prolong the QT interval, increasing risk of torsades de pointes 7
- Avoid in patients with:
- Known QT prolongation
- Uncorrected hypokalemia or hypomagnesemia
- Concurrent use of other QT-prolonging drugs
- Clinically significant bradycardia 7
Hepatic Impairment
- Use with caution in patients with impaired hepatic function 2, 7
- Monitor for signs of hepatotoxicity (jaundice, dark urine, abdominal pain)
Infantile Hypertrophic Pyloric Stenosis (IHPS)
- While azithromycin has lower risk than erythromycin, infants <1 month receiving any macrolide should be monitored for IHPS 2
- Signs include projectile vomiting, irritability, and decreased feeding
Drug Interactions
Significant Interactions to Avoid
- Antacids containing aluminum or magnesium: Reduce azithromycin absorption; separate administration by at least 2 hours 2, 7
- Warfarin: Monitor INR closely; azithromycin may potentiate anticoagulant effects 7
- Digoxin: Increased digoxin levels possible; monitor digoxin concentrations 2, 7
- Ergot alkaloids: Theoretical risk of ergotism 2
Moderate Interactions
- Nelfinavir significantly increases azithromycin concentrations (2.36-fold increase in Cmax) 7
- Cytochrome P450 substrates: Monitor when co-administered, though interactions are less common than with erythromycin 2, 7
Pharmacokinetic Considerations
Unique Tissue Distribution
- Azithromycin achieves tissue concentrations 1000-fold higher than serum in mononuclear and polymorphonuclear leukocytes 7, 9, 10
- Extended half-life of 68-72 hours allows for short-course therapy 7, 11
- Low serum concentrations (0.24-0.5 mcg/mL) are therapeutically adequate due to high tissue penetration 7
Food Effects
- Tablets: Food increases Cmax by 23% but does not affect AUC 7
- Suspension: Food increases Cmax by 56%; AUC unchanged 7
- Administer consistently with or without food for predictable absorption
Common Pitfalls and Clinical Pearls
Pitfall 1: Inappropriate Use for Severe Pneumococcal Pneumonia
Azithromycin has reduced activity against Streptococcus pneumoniae compared to erythromycin 10. For suspected pneumococcal CAP, combine with a beta-lactam or use alternative therapy.
Pitfall 2: Macrolide Resistance
Erythromycin-resistant organisms are cross-resistant to azithromycin 2, 7. Previous macrolide exposure or treatment failure necessitates alternative antibiotic selection.
Pitfall 3: Inadequate Monitoring in Neonates
For infants <1 month receiving azithromycin for pertussis, active surveillance for IHPS is mandatory despite lower risk than erythromycin 2. Educate parents about warning signs.
Pitfall 4: Single-Dose Therapy Misuse
The 1 g single-dose regimen is only validated for uncomplicated chlamydial urethritis/cervicitis 3. Do not extrapolate to other infections requiring multi-day therapy.
Clinical Pearl: Compliance Advantage
The once-daily dosing and short duration (3-5 days) significantly improve adherence compared to traditional 7-10 day regimens 9, 10, 11. This is particularly valuable in outpatient settings and for patients with compliance concerns.
Clinical Pearl: Pregnancy Category
Azithromycin is FDA Pregnancy Category B 2, making it a reasonable option when macrolide therapy is indicated during pregnancy, though doxycycline and fluoroquinolones should be avoided.
Adverse Effects Profile
Common (>1%)
- Gastrointestinal: Diarrhea, nausea, abdominal pain (most frequent) 2, 7
- Generally mild to moderate; rarely require discontinuation (0.7% vs 2.6% for comparators) 9
Serious but Rare
- Hepatotoxicity (cholestatic jaundice) 7
- Cardiac arrhythmias (QT prolongation, torsades de pointes) 7
- Clostridioides difficile infection 12
- Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) 7
Pediatric-Specific